Author’s response to reviews

Title: Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival

Authors:
Alessio MORGANTI (amorganti60@gmail.com)
Francesco CELLINI (f.cellimmd@gmail.com)
Milly BUWENGE (mbuwenge@gmail.com)
Alessandra ARCELLI (aleurceese@hotmail.it)
Sergio ALFIERI (sergio.alfieri@unicatt.it)
Felipe CALVO (felipe.calvo@salud.madrid.org)
Riccardo CASADEI (riccardo.casadei@unibo.it)
Savino CILLA (savinocilla@gmail.com)
Francesco DEODATO (francesco.deodato@fgps.it)
Giancarmine DI GIOIA (giancarmine.digioia@gmail.com)
Mariacristina DI MARCO (mariacristina.dimarco@unibo.it)
Lorenzo FUCCIO (lorenzofuccio@gmail.com)
Federica BERTINI (federica.bertini.rt@gmail.com)
Alessandra GUIDO (alessandraguido2008@gmail.com)
Joseph HERMAN (jherma15@jhmi.edu)
Gabriella MACCHIA (macchiagabriella@gmail.com)
Bert MAIDMENT (BWM5J@hsemail.mcc.virginia.edu)
Robert MILLER (miller.robert@mayo.edu)
Francesco MINNI (francesco.minni@unibo.it)
Paolo PASSONI (passoni.paolo@hsr.it)
Chiara VALENTINI (chiara.valentini83@gmail.com)
RESPONSE TO THE EDITOR

Title: Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival
Journal: BMC Cancer
Submission ID: BCAN-D-19-00453

Comment 1:
In the ethics approval and consent to participate subsection of the declarations please include the full unabbreviated names of each participating center’s institutional review boards. Additionally, please touch on the matter of consent to participate and why it was not needed for your study due to being a retrospective analysis.
Answer 1:
Thank you so much for your suggestion. We have included the full unabbreviated names of each participating centers’ institutional review boards as noted in the ethics approval and consent to participate subsection of the declarations section, lines 57,58, page 17 and lines 1-17, page 18. Furthermore, in consent to participate of the declarations section, line 20-21, page 18, we have included the following statement “Only patients who gave their written informed consent for the scientific use of their data were included in this analysis. “

Comment 2:
We strongly encourage all authors to share their raw data, either by providing it in a supplementary file, making it available on request to the authors, or depositing it in a public repository and providing the details on how to access it in this section. If you do not wish to share your data, please clearly state this in this section along with a justification. Data availability statements can take one of the following forms (or a combination of more than one if required for multiple datasets):
Answer 2:
Thank you so much for your suggestion. Following an agreement between participating centers, we
have added to the Availability of data and material of the declarations section, line 25-28, page 18 the following statement “The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request“

Comment 3:
Please provide a “List of abbreviations” subsection after the Conclusions section. If abbreviations are used in the text, they should be defined in the text at first use and included in this list.
Answer 3:
Thank you so much. The List of abbreviations subsection has been provided on line 21-51, page 17.

Comment 4:
At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.

Answer 4:
Thank you so much. We have followed and adhered to the above suggestions.